Covered recipient · General Payments record
SANDEEP BANSAL
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$244,810.48
302 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $194,451.25 | 61 |
| Travel and Lodging | $29,196.53 | 72 |
| Consulting Fee | $12,902.50 | 8 |
| Food and Beverage | $7,060.20 | 160 |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,200.00 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $62,076.37 | 47 |
| GENZYME CORPORATION | $60,634.51 | 31 |
| GlaxoSmithKline, LLC. | $48,100.68 | 79 |
| AstraZeneca Pharmaceuticals LP | $39,930.72 | 67 |
| Mylan Specialty L.P. | $8,343.82 | 10 |
| Noah Medical Corporation | $7,566.67 | 5 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $7,012.05 | 9 |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,726.04 | 8 |
| Regeneron Pharmaceuticals, Inc. | $4,592.50 | 2 |
| Galvanize Therapeutics, Inc | $400.00 | 1 |
| INTUITIVE SURGICAL, INC. | $381.29 | 7 |
| Actelion Pharmaceuticals US, Inc. | $244.07 | 7 |
| Novo Nordisk Inc | $144.61 | 2 |
| Novartis Pharmaceuticals Corporation | $142.74 | 5 |
| Biosense Webster, Inc. | $140.56 | 2 |
| Amgen Inc. | $112.30 | 3 |
| Philips North America LLC | $75.67 | 4 |
| Electromed, Inc. | $56.36 | 3 |
| Merck Sharp & Dohme LLC | $33.52 | 2 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $29.28 | 5 |
| PFIZER INC. | $22.98 | 1 |
| Insmed, Inc. | $22.05 | 1 |
| Pulmonx Corporation | $21.69 | 1 |
Page 2 of 7; records 51–100 of 302 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SANDEEP BANSAL
NPI 1215105267 · CMS profile ID 99969
Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
DU BOIS, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 7; records 51–100 of 302 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1215105267?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SANDEEP BANSAL, NPI 1215105267, CMS profile ID 99969. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 302 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215105267?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). SANDEEP BANSAL, NPI 1215105267, CMS profile ID 99969. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 302 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215105267?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- SANDEEP BANSAL, NPI 1215105267, CMS profile ID 99969, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 7; records 51–100 of 302 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1215105267?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
302 matching records · $244,810.48 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 302.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,050.00 | 11/14/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104698158 | CMS |
| GENZYME CORPORATION | $23.72 | 11/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139825448 | CMS |
| Regeneron Healthcare Solutions, Inc. | $33.11 | 11/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114004991 | CMS |
| Regeneron Healthcare Solutions, Inc. | $118.08 | 11/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114004993 | CMS |
| GlaxoSmithKline, LLC. | $44.46 | 11/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116656555 | CMS |
| Mylan Specialty L.P. | $61.90 | 11/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147359994 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $27.26 | 11/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117917397 | CMS |
| GlaxoSmithKline, LLC. | $3,900.00 | 11/08/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115884753 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.84 | 11/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105623791 | CMS |
| GlaxoSmithKline, LLC. | $1,300.00 | 11/06/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116026850 | CMS |
| GlaxoSmithKline, LLC. | $41.79 | 11/05/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116298086 | CMS |
| GlaxoSmithKline, LLC. | $264.03 | 11/05/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116500387 | CMS |
| GlaxoSmithKline, LLC. | $31.02 | 11/05/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116532722 | CMS |
| GlaxoSmithKline, LLC. | $332.09 | 11/05/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116733904 | CMS |
| GlaxoSmithKline, LLC. | $13.28 | 11/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116555875 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.90 | 10/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105398944 | CMS |
| Regeneron Healthcare Solutions, Inc. | $5,428.00 | 10/31/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114004987 | CMS |
| Regeneron Healthcare Solutions, Inc. | $8,768.00 | 10/31/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114004989 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,261.00 | 10/30/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137480276 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $82.44 | 10/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117917401 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,180.50 | 10/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114004981 | CMS |
| Regeneron Healthcare Solutions, Inc. | $451.33 | 10/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114004983 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,043.90 | 10/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114004985 | CMS |
| Insmed, Inc. | $22.05 | 10/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089559230 | CMS |
| Regeneron Healthcare Solutions, Inc. | $114.86 | 10/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114004979 | CMS |
| Actelion Pharmaceuticals US, Inc. | $15.82 | 10/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078908833 | CMS |
| Regeneron Healthcare Solutions, Inc. | $55.43 | 10/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114004977 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.21 | 10/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105424575 | CMS |
| AstraZeneca Pharmaceuticals LP | $537.00 | 10/19/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104786738 | CMS |
| GENZYME CORPORATION | $32.73 | 10/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139825440 | CMS |
| Novo Nordisk Inc | $125.00 | 10/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1096890938 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,670.00 | 10/17/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114004975 | CMS |
| GENZYME CORPORATION | $124.97 | 10/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139825572 | CMS |
| GENZYME CORPORATION | $8,768.00 | 10/16/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139825574 | CMS |
| GENZYME CORPORATION | $104.34 | 10/16/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139825576 | CMS |
| GENZYME CORPORATION | $1,222.81 | 10/16/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139825578 | CMS |
| GlaxoSmithKline, LLC. | $1,300.00 | 10/15/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116357324 | CMS |
| GlaxoSmithKline, LLC. | $1,300.00 | 10/15/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116415129 | CMS |
| GlaxoSmithKline, LLC. | $3,900.00 | 10/15/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116621541 | CMS |
| GlaxoSmithKline, LLC. | $19.88 | 10/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116327594 | CMS |
| Noah Medical Corporation | $3,200.00 | 10/08/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143649831 | CMS |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $10.72 | 10/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1080693630 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.63 | 10/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104330720 | CMS |
| GlaxoSmithKline, LLC. | $5.00 | 10/03/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115940119 | CMS |
| GlaxoSmithKline, LLC. | $106.08 | 10/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116266217 | CMS |
| GlaxoSmithKline, LLC. | $104.34 | 10/03/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116532516 | CMS |
| Electromed, Inc. | $16.96 | 10/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137879255 | CMS |
| GlaxoSmithKline, LLC. | $1,300.00 | 09/30/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115818548 | CMS |
| GlaxoSmithKline, LLC. | $3,900.00 | 09/30/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116503425 | CMS |
| Regeneron Healthcare Solutions, Inc. | $18.20 | 09/30/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114004973 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,140,697.05 | 330 |
| PY2024 | Recipient | $1,379.64 | 7 |
| PY2024 | Principal investigator | $2,630,112.11 | 233 |
| PY2023 | Principal investigator | $1,341,166.54 | 108 |
| PY2022 | Principal investigator | $508,223.05 | 63 |
| PY2021 | Principal investigator | $499,768.78 | 77 |
| PY2020 | Principal investigator | $154,747.10 | 16 |
| PY2019 | Principal investigator | $173,088.95 | 13 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
330 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $20,867.98 | 12/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) | No dispute reported | 06/30/2026 | 1185555487 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,982.00 | 12/22/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226131096 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $874.61 | 12/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease COPD with a History of COPD Exacerbations OBERON | No dispute reported | 06/30/2026 | 1185555479 |
| Principal investigator 1 | PFIZER INC. | $1,339.39 | 12/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOC CENTRAL PA | AN INTERVENTIONAL PHASE 23 RANDOMIZED DOUBLEBLIND THIRD PARTYUNBLINDED PLACEBOCONTROLLED PARALLELGROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH MODERATETOSEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD | No dispute reported | 06/30/2026 | 1228814920 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 12/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184277248 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $750.00 | 12/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184277250 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 12/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184277252 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 12/17/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640897 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $547.50 | 12/17/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640899 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.88 | 12/17/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640901 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.30 | 12/17/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640903 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $60.00 | 12/17/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640905 |
| Principal investigator 1 | Genentech, Inc. | $1,120.00 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES O | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211586984 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $12,131.60 | 12/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations | No dispute reported | 06/30/2026 | 1185555473 |
| Principal investigator 1 | Genentech, Inc. | $1,721.66 | 12/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES O | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211586979 |
| Principal investigator 1 | Genentech, Inc. | $3,450.00 | 12/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587149 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $651.00 | 12/05/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220812828 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,712.20 | 12/05/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812874 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,300.00 | 12/05/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812876 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $160.00 | 12/05/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812878 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 12/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640889 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 12/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640891 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 12/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640893 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.81 | 12/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220641003 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $14,033.10 | 11/26/2025 | Non-covered Recipient Entity CLINICAL LABORATORIES OF LINCOLN | A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) | No dispute reported | 06/30/2026 | 1185555485 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.50 | 11/26/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640919 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 11/26/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640921 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 11/26/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640923 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.50 | 11/24/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640913 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 11/24/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640915 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 11/24/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640917 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $21,114.14 | 11/24/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226131083 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $50.00 | 11/24/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226131086 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,500.00 | 11/24/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226131089 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,620.00 | 11/24/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226131091 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $52,050.00 | 11/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD | No dispute reported | 06/30/2026 | 1185555495 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 11/19/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640895 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $15,000.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST | No dispute reported | 06/30/2026 | 1192175238 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $548.00 | 11/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192179358 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.87 | 11/07/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640867 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.72 | 11/07/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640869 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.70 | 11/07/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640871 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.60 | 11/07/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640873 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.39 | 11/07/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640875 |
| Principal investigator 1 | Genentech, Inc. | $200.00 | 11/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587141 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $435.00 | 11/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192173341 |
| Principal investigator 1 | Pulmonx Corporation | $1,193.75 | 11/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES | Zephyr Valve Registry | No dispute reported | 06/30/2026 | 1199558957 |
| Principal investigator 1 | Genentech, Inc. | $55,369.00 | 11/03/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211587144 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 11/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 11/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640885 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 11/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640887 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.81 | 11/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220641011 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,000.00 | 10/29/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184253973 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $40.00 | 10/29/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184253975 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $80.00 | 10/29/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184253977 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $40.00 | 10/29/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184253979 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 10/29/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184253981 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 10/27/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220641005 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $650.00 | 10/27/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220812820 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $182.95 | 10/27/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220812822 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $21,500.00 | 10/27/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220812824 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,175.00 | 10/27/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226131080 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,025.04 | 10/22/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812872 |
| Principal investigator 1 | GENZYME CORPORATION | $21,344.00 | 10/20/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | Evaluate how dupilumab can alter the trajectory of COPD by modifying disease progression | No dispute reported | 06/30/2026 | 1226131075 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,364.00 | 10/20/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226131072 |
| Principal investigator 1 | AstraZeneca UK Limited | $750.00 | 10/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium Dose Inhaled Corticosteroid Plus Long acting 2 Agonist | No dispute reported | 06/30/2026 | 1185555489 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,829.24 | 10/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | REAL-WORLD EFFECTIVENESS OF MEPOLIZUMAB IN TREATING CHRONIC OBSTRUCTIV | No dispute reported | 06/30/2026 | 1192175230 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,100.00 | 10/14/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226131068 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $650.00 | 10/08/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220812826 |
| Principal investigator 1 | Pulmonx Corporation | $1,567.00 | 10/08/2025 | Non-covered Recipient Entity WCG IRB LLC | Zephyr Valve Registry | No dispute reported | 06/30/2026 | 1199558854 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $21,405.40 | 10/06/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812870 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $401.50 | 10/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1192179376 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 10/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640877 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 10/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640879 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 10/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640881 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.81 | 10/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220641009 |
| Principal investigator 1 | Verona Pharma, Inc. | $11,825.00 | 10/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES O | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891401 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,500.00 | 10/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES O | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891403 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,300.00 | 10/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES O | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891405 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,806.00 | 09/29/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226131062 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $434.00 | 09/25/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220812818 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $757.90 | 09/24/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640843 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,606.00 | 09/24/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640845 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $67.28 | 09/24/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640847 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $327.75 | 09/24/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640849 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.60 | 09/24/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640851 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $21.70 | 09/24/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640853 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $155.00 | 09/24/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640855 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $61.07 | 09/24/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640995 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.73 | 09/24/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640997 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.68 | 09/24/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640999 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.50 | 09/24/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220641001 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $182.95 | 09/24/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192177040 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,000.00 | 09/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192173338 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,500.00 | 09/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192175234 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,001.35 | 09/18/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812864 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,313.00 | 09/15/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226131030 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,756.00 | 09/15/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226131033 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $11,152.00 | 09/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T | No dispute reported | 06/30/2026 | 1192175226 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.00 | 09/10/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812866 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $80.00 | 09/10/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812868 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.01 | 09/08/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640907 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 09/08/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640909 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 09/08/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640911 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $603.00 | 09/08/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192123568 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.70 | 09/04/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640857 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.60 | 09/04/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640859 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.39 | 09/04/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640861 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.87 | 09/04/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640863 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.72 | 09/04/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640865 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.87 | 09/04/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640925 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.72 | 09/04/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640927 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.70 | 09/04/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640929 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.60 | 09/04/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640931 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.39 | 09/04/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640933 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,252.00 | 09/03/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226131042 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,846.00 | 09/03/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226131044 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $92.00 | 09/03/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226131049 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $45.36 | 09/03/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226131051 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $200.00 | 09/03/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226131054 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 09/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640821 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 09/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640823 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 09/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640825 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 09/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640827 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 09/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640829 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.81 | 09/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220641007 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 08/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211587091 |
| Principal investigator 1 | Genentech, Inc. | $4,867.00 | 08/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211587094 |
| Principal investigator 1 | Genentech, Inc. | $331.00 | 08/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211587099 |
| Principal investigator 1 | Genentech, Inc. | $2,000.00 | 08/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211587103 |
| Principal investigator 1 | Genentech, Inc. | $678.40 | 08/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211587107 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 08/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211587111 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 08/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211587115 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 08/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211587119 |
| Principal investigator 1 | Genentech, Inc. | $2,405.40 | 08/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211587124 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 08/26/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640993 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $750.00 | 08/25/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226131038 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $126.54 | 08/25/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226131057 |
| Principal investigator 1 | Genentech, Inc. | $360.00 | 08/22/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211587131 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,000.00 | 08/22/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192177036 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $372.00 | 08/20/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1192179368 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $750.00 | 08/18/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226131018 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,136.20 | 08/14/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812854 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 08/11/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226131013 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 08/11/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226131025 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.00 | 08/07/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812856 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.00 | 08/07/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812858 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,300.00 | 08/07/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812860 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,224.00 | 08/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1192123577 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,532.00 | 08/04/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226130986 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $65.00 | 08/04/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226130991 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $50.00 | 08/04/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226130996 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 08/04/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226131004 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 08/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640809 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 08/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640811 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 08/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640813 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $785.00 | 08/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640815 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 08/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640817 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 08/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640819 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 08/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220640949 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,239.80 | 08/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192123562 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,466.00 | 08/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192123583 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $14,500.00 | 08/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192175251 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 07/29/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812852 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $174.90 | 07/28/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640831 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 07/28/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640833 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $401.50 | 07/28/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640835 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.28 | 07/28/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640837 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $65.55 | 07/28/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640839 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.00 | 07/28/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640841 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $359.64 | 07/28/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640981 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $328.50 | 07/28/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640983 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $305.35 | 07/28/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640985 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $82.92 | 07/28/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640987 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.16 | 07/28/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640989 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $71.50 | 07/28/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640991 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 07/28/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226130999 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,575.00 | 07/28/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226131007 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,904.00 | 07/25/2025 | Non-covered Recipient Entity CLINICAL LABORATORIES OF LINCOLN | A Multicenter Open label Phase 3B Efficacy and Safety Study of Tezepelumab 210 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use and Asthma Exacerbations in Adult Subjects with Severe Asthma on High Dose Inhaled Corticosteroid plus Long acting B2 Agonist and Chronic Oral Corticosteroid Therapy | No dispute reported | 06/30/2026 | 1185555493 |
| Principal investigator 1 | Genentech, Inc. | $898.00 | 07/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587135 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,337.50 | 07/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192179355 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $900.00 | 07/21/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226130979 |
| Principal investigator 1 | Genentech, Inc. | $33,437.00 | 07/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211587127 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,500.00 | 07/14/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226130966 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,100.00 | 07/14/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226130983 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $23,445.05 | 07/10/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812850 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $12,200.00 | 07/09/2025 | Non-covered Recipient Entity CLINICAL LABORATORIES OF LINCOLN | A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inhaled corticosteroids | No dispute reported | 06/30/2026 | 1185555497 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.00 | 07/07/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812848 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 07/07/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226130970 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $63,377.00 | 07/07/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226130973 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $20,014.14 | 07/02/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226130962 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 07/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640803 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 07/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640805 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 07/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640807 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 07/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220640947 |
| Principal investigator 1 | PFIZER INC. | $12,500.00 | 06/26/2025 | Non-covered Recipient Entity Clinical Research Associates of Central PA LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228851565 |
| Principal investigator 1 | Genentech, Inc. | $40.00 | 06/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES O | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211586963 |
| Principal investigator 1 | Genentech, Inc. | $320.00 | 06/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES O | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211586975 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,608.00 | 06/23/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226130958 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 06/20/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | PhII - BI 1839100 in IPF associated with chronic cough | No dispute reported | 06/30/2026 | 1220812884 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $690.00 | 06/19/2025 | Non-covered Recipient Entity ADVARRA | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192123588 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,211.10 | 06/17/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | PhII - BI 1839100 in IPF associated with chronic cough | No dispute reported | 06/30/2026 | 1220812882 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $649.80 | 06/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192179363 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,868.75 | 06/16/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226130951 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $157.00 | 06/16/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226130955 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500.00 | 06/12/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812844 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500.00 | 06/12/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812846 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $21,148.90 | 06/11/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812842 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,483.90 | 06/09/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226130942 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500.00 | 06/06/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812862 |
| Principal investigator 1 | Genentech, Inc. | $2,694.00 | 06/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587075 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 06/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640779 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 06/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640781 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 06/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640783 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 06/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220640945 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,300.00 | 06/01/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812840 |
| Principal investigator 1 | AstraZeneca UK Limited | $14,062.00 | 05/28/2025 | Non-covered Recipient Entity CLINICAL LABORATORIES OF LINCOLN | BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium Dose Inhaled Corticosteroid Plus Long acting 2 Agonist | No dispute reported | 06/30/2026 | 1185555491 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $174.90 | 05/27/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640791 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 05/27/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640793 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $401.50 | 05/27/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640795 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.28 | 05/27/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640797 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $65.55 | 05/27/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640799 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.00 | 05/27/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640801 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.66 | 05/27/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640977 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 05/27/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640979 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $140.97 | 05/27/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226130930 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $123,322.41 | 05/27/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226130933 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,100.00 | 05/27/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226130938 |
| Principal investigator 1 | Genentech, Inc. | $392.85 | 05/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587065 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 05/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192177031 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,800.00 | 05/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 1192175247 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $790.00 | 05/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192175255 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $78,426.30 | 05/13/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812838 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $157.00 | 05/12/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226130947 |
| Principal investigator 1 | Genentech, Inc. | $17,062.00 | 05/09/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587079 |
| Principal investigator 1 | Genentech, Inc. | $41,922.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES O | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211586967 |
| Principal investigator 1 | Genentech, Inc. | $32,325.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES O | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211586971 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,202.40 | 05/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192175259 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $140.97 | 05/05/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226130909 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 05/05/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226130926 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 05/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640773 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 05/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640775 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 05/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640777 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $785.00 | 05/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640785 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 05/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640787 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 05/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220640789 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 05/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220640943 |
| Principal investigator 1 | Genentech, Inc. | $51,544.00 | 04/30/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587087 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,700.00 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226130890 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,300.00 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226130905 |
| Principal investigator 1 | Genentech, Inc. | $34,124.00 | 04/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587062 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,413.60 | 04/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192177061 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $37,940.00 | 04/24/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES | ANCHOR | No dispute reported | 06/30/2026 | 1185555481 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 04/21/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226130881 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,700.00 | 04/21/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226130886 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 04/21/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226130897 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,500.00 | 04/21/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226130901 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 04/14/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226130913 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $900.00 | 04/14/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226130918 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 04/14/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226130922 |
| Principal investigator 1 | Genentech, Inc. | $15,266.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587083 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,887.00 | 04/07/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226130873 |
| Principal investigator 1 | Genentech, Inc. | $20,654.00 | 04/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587070 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $722.00 | 04/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192177048 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,399.00 | 04/02/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226130870 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 04/02/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226130875 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 04/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220640941 |
| Principal investigator 1 | Ethicon Inc. | $5,000.00 | 04/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CEN TRAL PA LLC | Fluoroscopy Image Acquisition while using the Monarch Platform - Bronchoscopy | No dispute reported | 06/30/2026 | 1174996252 |
| Principal investigator 1 | Genentech, Inc. | $12,572.00 | 03/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587016 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 03/25/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640969 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 03/25/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640971 |
| Principal investigator 1 | Genentech, Inc. | $13,470.00 | 03/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587001 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,279.00 | 03/17/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226130847 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,281.00 | 03/10/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226130865 |
| Principal investigator 1 | Genentech, Inc. | $15,872.00 | 03/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587013 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $922.00 | 03/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192179380 |
| Principal investigator 1 | Genentech, Inc. | $47,434.00 | 03/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587024 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $450.00 | 03/04/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226130851 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,000.00 | 03/04/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226130854 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,000.00 | 03/04/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation | No dispute reported | 06/30/2026 | 1226130862 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $650.00 | 03/03/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812832 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $650.00 | 03/03/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812834 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $605.00 | 03/03/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812836 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 03/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220640937 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $299.70 | 02/25/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640957 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $255.50 | 02/25/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640959 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $488.56 | 02/25/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640961 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $103.65 | 02/25/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640963 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.44 | 02/25/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640965 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $57.00 | 02/25/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640967 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,630.55 | 02/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192127785 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $230,959.71 | 02/24/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES | The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod | No dispute reported | 06/30/2026 | 1185555475 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,500.00 | 02/24/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192175243 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $650.00 | 02/19/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | PhII - BI 1839100 in IPF associated with chronic cough | No dispute reported | 06/30/2026 | 1220812880 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $950.00 | 02/18/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226130868 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $29,649.79 | 02/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES | A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the United States | No dispute reported | 06/30/2026 | 1185555483 |
| Principal investigator 1 | Genentech, Inc. | $17,712.00 | 02/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211586997 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $39,203.65 | 02/10/2025 | Non-covered Recipient Entity Clinical Research Associates of Central | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812830 |
| Principal investigator 1 | Genentech, Inc. | $45,671.00 | 02/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211587058 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $893.00 | 02/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192177045 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $755.00 | 02/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192177053 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,736.00 | 02/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192177057 |
| Principal investigator 1 | Genentech, Inc. | $21,879.00 | 02/06/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211587054 |
| Principal investigator 1 | Genentech, Inc. | $21,326.00 | 02/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211586992 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $211.00 | 02/04/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226130843 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $798.00 | 02/03/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192179384 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 02/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220640935 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,008.10 | 01/31/2025 | Non-covered Recipient Entity CLINICAL LABORATORIES OF LINCOLN | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations | No dispute reported | 06/30/2026 | 1185555501 |
| Principal investigator 1 | Genentech, Inc. | $37,848.00 | 01/31/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587009 |
| Principal investigator 1 | Genentech, Inc. | $74,104.00 | 01/29/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211586988 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $103.65 | 01/27/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640951 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16.80 | 01/27/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640953 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $67.00 | 01/27/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640955 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 01/27/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640973 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $610.70 | 01/27/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220640975 |
| Principal investigator 1 | Genentech, Inc. | $37,804.00 | 01/24/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587020 |
| Principal investigator 1 | Genentech, Inc. | $15,018.00 | 01/22/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587029 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,388.00 | 01/21/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226130857 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $20,174.71 | 01/17/2025 | Non-covered Recipient Entity CLINICAL LABORATORIES OF LINCOLN | A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) | No dispute reported | 06/30/2026 | 1185555477 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $27,190.26 | 01/17/2025 | Non-covered Recipient Entity CLINICAL LABORATORIES OF LINCOLN | A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease COPD with a History of COPD Exacerbations OBERON | No dispute reported | 06/30/2026 | 1185555499 |
| Principal investigator 1 | Genentech, Inc. | $52,260.00 | 01/13/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211587005 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,529.00 | 01/13/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192179372 |
| Principal investigator 1 | Genentech, Inc. | $2,600.00 | 01/09/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211587033 |
| Principal investigator 1 | Genentech, Inc. | $15,557.00 | 01/09/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211587041 |
| Principal investigator 1 | Genentech, Inc. | $5,218.00 | 01/09/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211587050 |
| Principal investigator 1 | Genentech, Inc. | $486.59 | 01/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211587038 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,099.00 | 01/06/2025 | Non-covered Recipient Entity Clinical Research Associates Of Central PA LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226130878 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 01/03/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211587045 |
| Principal investigator 1 | Amgen Inc. | $52,185.20 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ASSOCIATES OF CENTRAL PENNSYLVANIA | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1246640307 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 01/01/2025 | Non-covered Recipient Entity Penn Highlands Du Bois Emergency Department And Trauma Center | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220640939 |